Opendata, web and dolomites

BMPARK SIGNED

Development of BMP2 Neurotrophic Therapy for Parkinson’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BMPARK project word cloud

Explore the words cloud of the BMPARK project. It provides you a very rough idea of what is the project "BMPARK" about.

hallmarks    scientific    protect    bodies    molecular    relevance    neurite    intraneuronal    communication    accumulation    levels    mechanism    socioeconomic    plans    vectors    stakeholders    century    extensive    neurodegenerative    direct    neurotrophic    career    people    me    nigra    axons    paralleled    lewy    context    alpha    neuroprotective    substantia    demographic    training    bmp2    morphogenetic    predominantly    signalling    annum    rat    modifying    degeneration    highlight    individuals    million    societal    dopamine    transgene    multidisciplinary    investigation    bmp    worldwide    neurons    contribution    clinical    double    therapy    pd    maturity    viral    motor    midbrain    efficacy    billion    despite    function    2030    therapies    disease    consist    transformative    date    intensive    parkinson    professional    13    protein    aging    progressive    region    economy    synuclein    dopaminergic    model    inclusions    trials    bone    total    half    independence    neuropathological    projected    brain   

Project "BMPARK" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK 

Organization address
address: WESTERN ROAD
city: Cork
postcode: T12 YN60
website: www.ucc.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 184˙590 €
 EC max contribution 184˙590 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK IE (Cork) coordinator 184˙590.00

Map

 Project objective

Parkinson’s Disease (PD) is a progressive neurodegenerative disease. PD affects more than 6 million people worldwide while 1.2 million people have PD in Europe. For the European economy PD has a total socioeconomic cost of €13.9 billion per annum. With the aging demographic the number of individuals affects by PD are projected to double by 2030 highlight the need for disease modifying therapies. The neuropathological hallmarks of PD are the progressive loss of dopaminergic neurons in a region of the brain known as the substantia nigra in the midbrain, and the accumulation of intraneuronal inclusions called Lewy bodies and lewy neurite that consist predominantly of a protein called α-synuclein. Despite over half a century of investigation, there is no disease modifying therapy for PD. I propose that a protein called bone morphogenetic protein (BMP)2 can protect midbrain dopaminergic neurons in the PD brain. BMP2 is distinct from other neurotrophic factors used in the clinical trials to date in that it has a different signalling mechanism that can be targeted to protect dopaminergic neurons. Here I will assess the neuroprotective efficacy of viral vectors carrying the BMP2 transgene in the rat α-synuclein model of PD. I will determine if this molecular therapy can protect dopamine neurons and their axons against α-synuclein induced degeneration to maintain brain dopamine levels and improve motor function. To do this, I will use a multidisciplinary approach which will be paralleled by intensive training and career development opportunities to enable me to make a transformative contribution to knowledge and to achieve professional maturity and independence. In this way, this work has direct relevance for the future development of neurotrophic factors for clinical use in PD and the extensive dissemination and communication plans to target all stakeholders will ensure both societal and scientific impact in an European context and also for individuals with PD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BMPARK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BMPARK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

QuanToPol (2020)

Quantum Topological Polaritonics

Read More  

TOPOCIRCUS (2019)

Simulations of Topological Phases in Superconducting Circuits

Read More  

EVENTS (2020)

Affective work-related daily events, and changing characteristics of the work context: New challenges for management practices to deliver employees’ well-being and workplace performance

Read More  
lastchecktime (2022-05-17 0:54:53) correctly updated